logo

CTMX

CytomX Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
consensus rating "Buy"
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About CTMX

Cytomx Therapeutics, Inc.

A leader in the field of conditionally activated oncology therapeutics

Pharmaceutical
Invalid Date
10/08/2015
NASDAQ Stock Exchange
119
12-31
Common stock
151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080
--
CytomX Therapeutics, Inc., was incorporated in Delaware in September 2010. The Company is a clinical-stage, oncology-focused biopharmaceutical company focused on the development of novel conditionally activated biologics designed to target the tumor microenvironment. The Company's proprietary, multifunctional, multimodal PROBODY technology platform is designed to enable the conditional activation of biotherapeutic drug candidates within tumor microcycles while minimizing drug activity in healthy tissues and circulation.

Company Financials

EPS

CTMX has released its 2024 Q4 earnings. EPS was reported at 0.22, versus the expected -0.11, beating expectations. The chart below visualizes how CTMX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CTMX has released its 2024 Q4 earnings report, with revenue of 38.09M, reflecting a YoY change of 43.17%, and net profit of 18.88M, showing a YoY change of 2155.20%. The Sankey diagram below clearly presents CTMX’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime